Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
Am J Hematol. 2012 Jul;87(7):724-6. doi: 10.1002/ajh.23184. Epub 2012 Mar 31.
Follicular lymphoma (FL) has variable progression and survival, and improved identification of patients at high risk for progression would aid in identifying patients most likely to benefit from alternative therapy.In a sample of 244 FL cases identified during a population-based case-control study of non-Hodgkin lymphoma (NHL), we examined 6,679 tag SNPs in 488 gene regions for associations with overall FL survival. Over a median follow-up of 89 months with 65 deaths in this preliminary study, we identified 5 gene regions (BMP7, GALNT12,DUSP2, GADD45B, and ADAM17) that were associated with overall survival from FL. Results did not meet the criteria for statistical significance after adjustment for multiple hypothesis testing. These results,which support a role for host factors in determining the variable progression of FL, serve as an initial examination that can inform future studies of genetic variation and FL survival. However, they require replication in independent populations, as well as assessment in rituximab-treated patients.
滤泡性淋巴瘤 (FL) 的进展和生存情况各不相同,因此更好地识别进展风险高的患者将有助于确定最有可能从替代治疗中获益的患者。在一项针对非霍奇金淋巴瘤 (NHL) 的基于人群的病例对照研究中确定的 244 例 FL 病例中,我们研究了 488 个基因区域中的 6679 个标签 SNP 与总体 FL 生存的相关性。在这项初步研究中,中位随访 89 个月,有 65 人死亡,我们确定了 5 个基因区域 (BMP7、GALNT12、DUSP2、GADD45B 和 ADAM17) 与 FL 的总体生存相关。在进行多次假设检验调整后,结果未达到统计学意义的标准。这些结果支持宿主因素在决定 FL 不同进展中的作用,是一个初步的研究,可以为未来的遗传变异和 FL 生存研究提供信息。然而,它们需要在独立人群中进行复制,并在利妥昔单抗治疗的患者中进行评估。